Nab-sirolimus plus letrozole for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent endometrioid endometrial cancer that has spread or cannot be surgically removed
- You have at least one tumor that can be measured on a CT or MRI scan
- You have had either no chemotherapy or only one type of chemotherapy for your advanced cancer, and if you had treatment, it must have helped shrink your tumor at least once
- You are 18 years or older and your overall health is good (ECOG performance status 0 or 1)
- You have not taken an mTOR inhibitor (like everolimus or sirolimus) before
- You are willing to use effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
This trial studies a combination of two oral drugs, elacestrant and everolimus, for advanced or recurrent endometrial cancer that is hormone receptor positive. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.